BCRP和Ki-67与乳腺癌新辅助化疗疗效的关系

摘要

目的:探讨乳腺癌组织中乳腺癌耐药蛋白(breast cancer resistance protein,BCRP)和Ki-67的表达与新辅助化疗疗效之间的关系.方法:回顾性分析我科2012 年10月至2014年8 月收治的Ⅱ-Ⅲ期乳腺癌新辅助化疗患者65例,采用免疫组化方法检测BCRP和Ki-67的表达,分析BCRP、Ki-67的表达水平与新辅助化疗疗效的关系.结果:原发性乳腺癌组织中BCRP的阳性表达率为67.7%.BCRP的表达水平与新辅助化疗后病理组织学反应有关,组织学显著反应组(病理反应4~5级)BCRP的表达水平明显低于非显著反应组(病理反应1~3级),差异有统计学意义(x2=12.77,P=0.001).化疗前Ki-67高表达组临床缓解率明显高于低表达组(x2=17.72,P<0.00). 结论: 联合检测乳腺癌组织中BCRP和Ki-67 的表达水平对新辅助化疗疗效有一定的预测价值.%Objective:To investigate whether the expression of BCRP and Ki-67 expression in breast cancer could predict the efficacy of neoadjuvant chemotherapy.Methods:This research retrospectively analyzed 65 patients, who were diagnosed as invasive ductal carcinomas in stage Ⅱ-Ⅲ admitted in the breast cancer center in our hospital and accepted NAC from October 2012 to Augest 2014.Immunohistochemical assay was used to detect the BCRP and Ki-67 protein levels of 65 breast cancer tissues obtained by core needle biopsy before neoadjuvant chemotherapy.The relationship of BCRP and Ki-67 expression with efficacy of neoadjuvant chemotherapy was statistically analyzed.Results:The positive expression rate of BCRP was 67.7% in patients with primary breast cancer.The expression of BCRP was associated with the pathological response after neoadjuvant chemotherapy.BCRP expression in group of major histological response(grade of 4~5) was significantly lower than that in group of non major histological response(grade of 1~3)(x2=12.77,P=0.001).Patients with Ki-67 over-expression were more sensitive than those with lower-expression(x2=17.72,P<0.00).Conclusion:The protein levels of BCRP and Ki-67 showed predictive value of the efficacy of neoadjuvant chemotherapy.